In addition, bortezomib constrains JAK-STAT activity by blocking the IL-6 receptor (a function opposite to IFN-α,β activity) and reduces inflammation, autophagy and angiogenesis in cancer cells [130]. The gene discussed is IFNA2; the disease is cancer.